-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
In This Section
-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
-
AIPLA CLE Webinar: Post-Grant Strategies for Correcting and Challenging Patent Claims
March 4, 2020 12:30 PM to 2:00 PM | 1.5 CLE Credits
This webinar will provide a summary of post-grant procedures and describe when, why, and how each procedure is useful (or not) to patent owners and third-party challengers.
News
-
PTAB Proposes Changes to Motion to Amend Practice in AIA Trials
November 1, 2018
The USPTO has published a Request for Comments (RFC) on a proposed procedure for motions to amend filed in AIA trials before the PTAB. -
Registration Open for Inventor STEPP Training
October 31, 2018
Registration is now open for the Feb. 5 - 7, 2019 USPTO Inventor 3-Day Course on Examination Practice and Procedure. -
CAFC Affirms Invalidation of Patents for MS Drug Copaxone
October 19, 2018
The Federal Circuit on October 12, 2018, affirmed a district court decision invalidating Teva’s patents for Copaxone, its best-selling multiple sclerosis drug. -
Cert. Denial Gives Comcast, Verizon Patent Win
October 18, 2018
The Supreme Court on October 15, 2018, declined to review a Federal Circuit decision affirming a district court’s holding that two of Two-Way Media Ltd.’s patents directed to internet streaming of video and audio were ineligible for protection. -
1st Circuit Reverses Class Certification in Asacol Antitrust Case
October 17, 2018
The US Court of Appeals for the First Circuit on October 15, 2018, reversed a district court order certifying a class of indirect purchasers of the drug Asacol to pursue antitrust claims against Allergan Inc., the drugmaker.